References
- Bechtel W. D., Mierau J., Brandt K., Foerster H. J., Pook K. H. Metabolic fate of [14C]brotizolam in rat, dog, monkey, and man. Arzneimittel Forschung 1986; 36: 578–586
- Borodny P. E., Michnewicz B. M. Metabolic disposition of isoxicam in man, monkey, dog and rat. Drug Metabolism and Disposition 1984; 12: 444–451
- Busch U., Heinzel G., Bozler G. Pharmacokinetics of 14C-labelled meloxicam: a new antiphlogistic drug in man. Proceedings of the XVIIth Ilar Congress of Rheumatology. 1989. Rio de JaneiroBrazil September, 1989; 17–23, Abstract
- Chatfield D. H., Hunter W. H. The metabolism of acetamidothiazoles in the rat. Biochemical Journal 1973; 134: 869–878
- Engelhardt G. Meloxicam, a potent inhibitor of COX-2. Proceedings of the 9th International Conference on Prostaglandins and Related Compounds. 1994a. FlorenceItaly 6–10 June, 1994; 82, Abstract
- Engelhardt G., Homma D., Schnitzler C. H. R. Meloxicam. A potent inhibitor of adjuvant arthritis in the rat. Scandinavian Journal of Rheumatology 1994b; 98(Suppl.), abstract 110
- Guentert T. W., Heintz R. C., Jolly R. Overview on the pharmacokinetics of Tenoxicam. European Journal of Rheumatology and Inflammation 1987; 9(2)15–25
- Hobbs D. C., Twomey T. M. Metabolism of sudoxican by the rat, dog and monkey. Drug Metabolism and Disposition 1977; 5: 75–81
- Hobbs D. C., Twomey T. M. Metabolism of piroxicam by laboratory animals. Drug Metabolism and Disposition 1981; 9: 114–118
- Huskisson E. C., Narjes H., Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 1994; 98(Suppl.), abstract 115
- Ichihara S., Ohtake M., Tomisawa H., Fukazawa H., Tateishi M. (1989b) Metabolism of non-steroidal antiinflammatory drugs containing beta-diketone moiety by leukocytes (a possible mechanism of antiinflammatory activity). Proceedings of the 19th Symposium on Drug Metabolism and Action, OsakaJapan, 27–28 October, 1988, 569, Journal of Pharmacobio-Dynamics, 12
- Ichihara S., Tomisawa H., Fukazawa H., Tateishi M. Involvement of leucocyte peroxidases in the metabolism of tenoxicam. Biochemical Pharmacology 1985; 34: 1337–1338
- Ichihara S., Tomisawa H., Fukazawa H., Tateishi M., Joly R., Heintz R. Oxidation of tenoxicam by leucocyte peroxidases and H2O2 produces novel products. Drug Metabolism and Disposition 1989a; 17: 463–468
- Ichihara S., Tsuyuki Y., Tomisawa H., Fukazawa H., Nakayama N., Tateishi M., Joly R. Metabolism of tenoxicam in rats. Xenobiotica 1984; 14: 727–739
- Kato R., Yamazoe Y. Hormonal regulation of cytochrome P450 in rat liver. Handbook of Experimental Pharmacology, J. B. Schenkmann, H. Greim. Springer, Berlin 1993; vol. 105: 447–459
- Leemann T., Transon C., Bonnabry P., Dayer P. A major role for cytochrome P-450TB(CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Under Experimental and Clinical Research 1993; 19: 189–195
- Lund B., Distel M. A double-blind placebo controlled study of three different doses of meloxiam in patients with osteoarthritis (OA) of the knee. Scandinavian Journal of Rheumatology 1994; 98(Suppl.), abstract 117
- Milligan P. A. Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high performance liquid chromatography. Journal of Chromatography, Biomedical Applications 1992; 576: 121–128
- Olkkola K. T., Brunetto A. V., Mattila M. J. Pharmacokinetics of oxicarn nonsteroidal anti-inflammatory agents. Clinical Pharmacokinetics 1994; 26: 107–120
- Ruijten H. M., van Amsterdam P. H., Bree H. D. Conical precolumn as loading buffer for the main column. Journal of Chromatography 1984; 314: 183–191
- Schmid J., Busch U., Heinzel G., Bozler G., Kaschke S., Kummer M. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metabolism and Disposition 1995; 23, (in press)
- Schmid J., Prox A., Busch U., Kaschke S., Sauter T. The biotransformation of meloxicam in man and rat. Scandinavian Journal of Rheumatology 1994; 98(Suppl.), abstract 118
- Schmid J., Roth W. HPLC-procedures for drug metabolism studies: The potential of column switching. Drug Metabolism, From Molecules to Man, D. J. Benford, J. W. Bridges, G. G. Gibson. Taylor & Francis, London 1987; 213–216
- Türck D., Busch U., Heinzel G., Narjes H., Nehmitz G. Effect of food on the pharmacokinetics of meloxican after oral administration. Clinical Drug Investigation 1995; 9: 270–276
- Woolf T. F., Black A., Hicks J. L., Lee H., Chuang C. C., Chang T. In vivo metabolism of isoxicam in rats, dogs, and monkeys. Drug Metabolism and Disposition 1989a; 17: 662–668
- Woolf T. F., Black A., Sedman A., Chang T. Metabolic disposition of the non-steroidal antiinflammatory agent Isoxicam in man. European Journal of Drug Metabolism and Pharmacokinetics 1992; 17: 21–27
- Woolf T. F., Radulovic L. L. Oxicams: metabolic disposition in man and animals. Drug Metabolism Reviews 1989b; 21: 255–276
- Zhao J., Leemann T., Dayer P. In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sciences 1992; 51: 575–81